ASH: CAR T-Cell Tx Offers Durable Response in Pre-Treated MM – MedPage Today
Medical Xpress |
ASH: CAR T-Cell Tx Offers Durable Response in Pre-Treated MM
MedPage Today ATLANTA – A single infusion of a gene therapy called bb2121 showed promise in heavily pre-treated multiple myeloma patients, offering a complete response that was sustained for beyond a year in some cases, researchers reported here. Of 18 patients … 'Unheard of' responses to bluebird CAR–T therapy seen in myeloma study CAR T, immunotherapy bring new hope for multiple myeloma patients #ASH17: The BCMA-targeted CAR–T bb2121 from bluebird and Celgene takes a star turn in the spotlight |
